公开(公告)号：US20230053846A1

公开(公告)日：2023-02-23

申请号：US17778593

申请日：2020-11-13

Applicant: OSAKA UNIVERSITY ,  TOSOH CORPORATION

Inventor： Motohide UEMURA ,  Norio NONOMURA ,  Takeshi UJIKE ,  Shohei MYOBA ,  Norihisa OHTAKE

IPC: G01N33/574 ,  C07K16/22

Abstract: A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.

公开(公告)号：US20230122642A1

公开(公告)日：2023-04-20

申请号：US17802354

申请日：2021-02-09

Applicant: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY ,  TOSOH CORPORATION

Inventor： Etsuko MIYAGI ,  Noriaki ARAKAWA ,  Ayase-shi OHTAKE ,  Shohei MYOBA

IPC: G01N33/574

Abstract: An object of the present invention is to provide a method for detecting malignant ovarian tumor as distinguished from benign ovarian tumor, and a reagent that can be used for the method. Provided are a method for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor, characterized by measuring the amount of TFPI2 in a sample from a patient, and a reagent for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor contains an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2.

公开(公告)号：US20230221322A1

公开(公告)日：2023-07-13

申请号：US17999772

申请日：2021-05-18

Applicant: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY ,  TOSOH CORPORATION

Inventor： Wataru SHIBATA ,  Yasuo TERAUCHI ,  Itaru ENDO ,  Yasuhiro SHIMIZU ,  Norihisa OHTAKE ,  Shohei MYOBA

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57438 ,  G01N33/6851 ,  G01N2333/4704

Abstract: An object of the invention is to provide a method for detecting pancreatic cancer and a reagent that can be used for the method. The method is a method for detecting pancreatic cancer, characterized by comprising measuring the amount of TFPI2 in a body fluid collected from a subject. In addition, an antibody that specifically recognizes the TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancer.

公开(公告)号：US20210190786A1

公开(公告)日：2021-06-24

申请号：US16080577

申请日：2017-02-23

Applicant: TOSOH CORPORATION

Inventor： Noriaki ARAKAWA ,  Hisashi HIRANO ,  Hiroji UEMURA ,  Yusuke ITO ,  Shohei MYOBA ,  Norihisa OHTAKE

IPC: G01N33/574 ,  C07K14/475 ,  C07K16/22

Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.

公开(公告)号：US20200256872A1

公开(公告)日：2020-08-13

申请号：US16643381

申请日：2018-08-22

Applicant: TOSOH CORPORATION

Inventor： Shohei MYOBA ,  Norihisa OHTAKE

IPC: G01N33/574 ,  G01N33/68

Abstract: The present invention provides a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. According to the present invention, cancer (excluding castration-resistant prostate cancer) is detected by measuring the intact growth and differentiation factor (GDF15) propeptide level, the GDF15 propeptide fragment level, or the total of the intact GDF15 propeptide level and the GDF15 propeptide fragment level, in a sample. The above described method for detecting cancer includes a method for detecting one or more selected from the group consisting of stomach cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer and esophageal cancer, and a method for distinguishing and detecting non-small cell lung cancer and small cell lung cancer. Further, a reagent for detecting cancer includes an antibody that specifically recognizes GDF15 propeptide.